Previous close | 86.20 |
Open | 86.20 |
Bid | 80.60 |
Ask | 84.55 |
Strike | 195.00 |
Expiry date | 2024-07-19 |
Day's range | 86.20 - 86.20 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Novavax gets green light from FDA, awaits CDC recommendation for booster COVID doses.
The Serum Institute of India has received a recommendation from WHO for malaria doses using a Novavax adjuvant.
(Bloomberg) -- Novavax Inc.’s updated version of its Covid-19 shot gained US regulators’ authorization for emergency use amid a rocky rollout of competitors’ offerings.Most Read from BloombergKey Taiwan Tech Firms Helping Huawei With China Chip PlantsWall Street Fear Gauge Ratchets Up After Jobs Data: Markets WrapKevin McCarthy Ousted as US House Speaker by Republican DissidentsWhy a US Recession Is Still Likely — and Coming SoonAirbnb Is Fundamentally Broken, Its CEO Says. He Plans to Fix It.Th